Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lama

Showing results (211-220 of 226) with videos related to

Pageof 23
Sort By:
Eclinicalmedicine|June 8, 2023
Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trialMariana Araújo-Pereira, Sonya Krishnan, Padmini Salgame, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2015
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyAshwin Balagopal, David M Asmuth, Wei-Teng Yang, et al.
Vaccine|July 7, 2021
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest periodYunda Huang, Kelly E Seaton, Martin Casapia, et al.
Lancet (London, England)|March 31, 2016
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trialMina C Hosseinipour, Gregory P Bisson, Sachiko Miyahara, et al.
The New England Journal of Medicine|March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related TuberculosisSusan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2015
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical TrialRami Kantor, Laura Smeaton, Saran Vardhanabhuti, et al.
The New England Journal of Medicine|October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosisDiane V Havlir, Michelle A Kendall, Prudence Ive, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Microbiology Spectrum|March 23, 2026
Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathwaysSean M Hughes, Fernanda L Calienes, Claire N Levy, et al.
Cell Reports. Medicine|October 5, 2020
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV InfectionSean M Hughes, Claire N Levy, Fernanda L Calienes, et al.
Pageof 23

Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
Eclinicalmedicine|June 8, 2023
Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trialMariana Araújo-Pereira, Sonya Krishnan, Padmini Salgame, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2015
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyAshwin Balagopal, David M Asmuth, Wei-Teng Yang, et al.
Vaccine|July 7, 2021
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest periodYunda Huang, Kelly E Seaton, Martin Casapia, et al.
Lancet (London, England)|March 31, 2016
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trialMina C Hosseinipour, Gregory P Bisson, Sachiko Miyahara, et al.
The New England Journal of Medicine|March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related TuberculosisSusan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2015
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical TrialRami Kantor, Laura Smeaton, Saran Vardhanabhuti, et al.
The New England Journal of Medicine|October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosisDiane V Havlir, Michelle A Kendall, Prudence Ive, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Microbiology Spectrum|March 23, 2026
Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathwaysSean M Hughes, Fernanda L Calienes, Claire N Levy, et al.
Cell Reports. Medicine|October 5, 2020
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV InfectionSean M Hughes, Claire N Levy, Fernanda L Calienes, et al.
Pageof 23